Grail Embarks Independently in the Public Markets Following Completion of Illumina Spin-Off
Cancer test maker Grail made its debut on the Nasdaq on Tuesday, marking a significant pivot nearly four years after its initial public offering plans were disrupted by a takeover from Illumina. This development follows a prolonged period of regulatory disputes involving both the U.S. Federal Trade Commission and the European Commission, which challenged the […]